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Abstract 
Objective. To review performance differences, with meta-analyses, between ecstasy 
(MDMA) users and non-users on a wider range of tasks requiring processing of 
visual/spatial information than in our previous narrative review of tasks requiring 
working memory executive resources. Method. Abstracting databases were 
searched using the United Kingdom NHS Evidence Health Information Resource. 
Inclusion criteria were publication in English language peer-reviewed journals, and to 
be reporting new findings regarding human ecstasy users’ performance on 
visual/spatial tasks. Data extracted included specific task demands, to provide a 
basis for meta-analyses for categories of tasks making similar demands. Results. 
Fifty-two studies were identified for review, although not all were suitable for meta-
analysis. Significant weighted mean effect sizes indicating poorer performance by 
ecstasy users compared to matched controls were found for tasks requiring recall of 
spatial stimulus elements, recognition of figures, and production/reproduction of 
figures. There was no evidence of a linear relationship between estimated ecstasy 
consumption and effect sizes. Conclusions. Given the networked nature of 
processing for spatial and non-spatial visual information, future scanning and 
imaging studies should focus on brain activation differences between ecstasy users 
and non-users in the context of specific tasks for the identification of loci of 
potentially compromised activity in users. 
 
 
 3 
Introduction 
The black market drug ‘ecstasy’ has been an important feature of illegal drug use 
since the late 1980s in many countries, with recent estimates of lifetime ‘ever use’ 
such as 2.6 million for 16 to 50 year olds in England Wales (Hoare & Moon, 2010), 
14.2 million for those aged 12 years or older in the United States (Substance Abuse 
and Mental Health Services Administration, 2010), and 1.5 million for those aged 14 
and older in Australia (Australian Institute of Health and Welfare, 2008). The 
dominant chemical constituent of ecstasy (3,4-methylenedioxymethamphetamine, or 
MDMA) is known to be neurotoxic with regard to serotonergic neurons in the brains 
of rats and primates (Puerta et al., 2009), and although the nature and duration of its 
effects on human brains has been hotly debated (Cowan, 2007), it is evident from 
scanning and imaging studies that the functioning of serotonergic neurons in a 
number of brain areas in ecstasy users can be altered in comparison to non-users. 
For example, using fMRI recordings of the blood-oxygen level dependent (BOLD) 
signal, Cowan et al. (2006) showed different activation patterns in the visual occipital 
areas of users in comparison to non-users in response to photic stimulation, whilst 
the use of SPECT has identified serotonergic axonal damage in thalamic and 
frontoparietal brain regions of users (de Win et al., 2008a, 2008b). McCann et al. 
(1998, 2005, 2008) examined the availability for binding of the presynaptic 
membrane serotonin transporter (SERT) using PET scanning, and reported 
significant global reductions in SERT binding activity in users compared to non-users 
in brain areas which included the dorsolateral prefrontal cortex (DLFPC), parietal 
cortex, temporal cortex, and occipital cortex. However, only the latest of these three 
studies investigated, and was therefore able to confirm, impaired cognitive 
performance and global SERT binding reductions in the same sample of ecstasy 
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users compared to non-users. However, SERT binding in fronto-striatal regions has 
been shown to be related to cognitive performance in healthy participants (Madsen 
et al., 2011). Whilst changes in SERT binding may be subject to different 
interpretations with regard to nature of the underlying neuronal damage (Reneman et 
al., 2006a), there is evidence that such changes may be reversible in humans with 
abstinence from ecstasy (Buchert et al., 2004; Selvaraj et al., 2009), although this 
may not be always be accompanied by equivalent levels of cognitive performance 
compared to non-users (Gouzoulis-Mayfrank & Daumann, 2009; Thomasius et al, 
2006). 
 
One of the cognitive functions potentially vulnerable to the disruption of serotonergic 
functioning is visuospatial memory. This has been demonstrated in humans by 
performance decrements related to administration of the 5-HT2A receptor anatagonist 
ketanserin (Wingen et al., 2007). Research into the effects of ecstasy use on 
visuospatial memory performance has produced contrasting results. We have 
previously reviewed findings from 18 studies which compared the performance of 
ecstasy users to that of non-users on tasks requiring the recall or recognition of 
specific spatial elements of a stimulus array (Murphy et al., 2009), and noted that 
where inter-group performance differences on computerised grids and block tapping 
tasks had been absent for simple versions of the task, increasing the performance of 
the task would sometimes lead to the emergence of significant differences. For 
example, this occurred where a spatial sequence had be recalled backwards rather 
than forwards (Halpern et al., 2004), or where additional spatial information 
processing demands were made of participants (Wareing et al., 2004, 2005).  Latent 
variable analysis has shown visuospatial memory performance to draw heavily upon 
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the executive resources of working memory (Miyake et al., 2001), and that this is the 
case whether the task in question requires only basic retention and retrieval, 
constituting simple visuospatial memory, or additional goal orientated processing of 
the stimulus array, constituting visuospatial working memory. Our previous review 
tentatively concluded that the level of executive processing demands made by a 
visuospatial task might have a role in mediating differences in performance levels 
between ecstasy users and non-users, and recommended that this be further 
investigated. 
 
With regard to neural structures, visuospatial memory has been shown to draw upon 
a network of structures involved with different aspects of the information processing 
required (see review by Zimmer, 2009) For example, the DLPFC appears to be 
concerned with processing spatial information, and also with the monitoring of 
information flow generally, as would be consistent with frontal lobe executive 
functioning more broadly. Parietal cortex has also been shown to contribute to the 
processing of spatial information, whilst temporal and occipital areas contribute to 
the processing of other stimulus features. Despite evidence for differentiation in brain 
areas processing spatial and other visual information, there is also evidence that 
both spatial and non-spatial visual stimuli draw upon common brain areas, including 
the DLPFC (Owen et al., 1998; Rypma, 2006), and primary visual occipital areas will 
process all visual stimuli from tasks. The widespread effects on brain functioning 
associated with ecstasy consumption discussed above, therefore have the potential 
to impair performance on visuospatial tasks in a combination of ways involving a 
range of neural locations. Consequently, task performance may conceivably suffer 
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due to impaired processing of spatial information, impaired monitoring of the flow of 
information, or impaired processing of nonspatial stimulus features. 
 
Our previous review of visuospatial performance in ecstasy users (Murphy et al., 
2009) had two important limitations, these being that it was entirely narrative with no 
quantitative analysis, and that only a limited range of visual tasks with a spatial 
dimension were examined. This present review aims to address both of these 
limitations. An exploration of a wider range of visual tasks is considered important 
because all visual stimuli inherently possess a spatial dimension.  The ability to 
compare abstract visual figures requires cortical processing of their spatial 
characteristics, even though the task of identifying whether two figures are the same 
or different would not generally be considered as a visuospatial task in the same way 
as a task requiring the recall of a spatial sequence for highlighted grid squares. 
Examination of potential ecstasy related effects with regard to differences in 
processing demands across tasks for visual and spatial information may therefore 
add to our knowledge of the neuropsychological consequences of using this drug. 
Given the range of tasks to be examined, the term ‘visual/spatial’ rather than 
‘visuospatial’ will be used in referring to tasks for the remainder of this review, in 
order to avoid any conflict with the traditional use of the latter term. In the light of 
criticisms of studies concerning ecstasy related cognitive performance effects 
generally in relation to not adequately controlling for potential confounds in their 
results (Rogers et al., 2009), attention will also be paid in this review to the methods 
used by studies to control for the potential effects of other drug use, intelligence, and 
demographic variables on their results.  
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Method 
Identification of studies 
A preliminary search of literature covering the period up to November 2009 was 
undertaken to identify publications relating to the effects of ecstacy (MDMA) on 
visual/spatial performance in humans. The Psychinfo, Pubmed, and Web of Science 
databases were initially searched using eight terms in which either ‘ecstasy’ or 
‘MDMA’ was paired, respectively, with ‘spatial’, ‘visual’, ‘visuospatial’, or ‘visuo-
spatial’. This preliminary search covered the period up to May 2010. In the second 
phase a further systematic search of the literature was undertaken to identify 
publications up to the end of 2010. Electronic databases Medline, Embase, and 
PsychInfo were searched via the United Kingdom NHS Evidence Health Information 
Resource. The ISI Web of knowledge was searched independently. All databases 
were cross-checked to avoid duplication. The following keywords, and their 
corresponding synonyms, were employed in the search: ecstasy, MDMA, visual, 
visuo-spatial or visuospatial, spatial and performance. In this second search it was 
possible to explode these terms utilising the relevant database thesaurus to ensure 
completeness of data.  
 
The search was restricted to English language publications with human participants. 
Other inclusion criteria were that studies had to be in peer-reviewed journals, and to 
be reporting new findings (including attempted replications) regarding visual/spatial 
memory performance with regard to ecstasy use. It was necessary for participants to 
have been abstinent from ecstasy and other drugs of misuse at the time of testing. 
By implication, therefore, studies which tested participants under the influence of 
ecstasy or another drug, animal studies, and studies published in a language other 
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than English were excluded from the review. Studies were also excluded if they were 
in the form of dissertations, conference presentations, reviews or meta-analyses, or 
used ‘concrete’ objects (including faces), as opposed to abstract figures, as stimuli in 
such a way which would be likely to recruit brain areas not recruited in other 
visual/spatial tasks (Haxby et al., 2000). A similar problem arose with the use of 
verbal items as stimuli, including digits, as there was the possibility of language 
related areas being recruited into participants’ stimulus processing and response 
selection, in a way distinct from other tasks (Gruber & von Crammon, 2003). In 
practice, studies were included if participants had been required to focus their 
response upon the spatial location of stimuli, such as in recalling a sequence of 
highlighted grid squares, but not if their response was focussed upon verbal aspects 
of the stimulus, such as naming a letter. Decisions involving inclusion in the review 
were based upon consensus between at least two reviewers. Inclusion in the review 
sample did not automatically imply inclusion in meta-analyses, as additional criteria 
regarding study design, tasks employed, and the reporting of data were relevant to 
these decisions and are discussed below (see Analytic Strategy). 
 
Data extraction 
For each study included in the review, details were recorded for each sub-group of 
participants regarding age, estimated lifetime ecstasy consumption, and time since 
last ecstasy use. These variables were recorded in the form in which they were 
reported, which generally involved mean values qualified by standard deviations. 
Where studies did not report data for abstinence duration from ecstasy prior to 
testing the minimum abstinence duration for participants’ inclusion in the study was 
recorded, if reported. Where studies did not report an estimate for lifetime ecstasy 
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consumption an implied estimate was calculated, if possible, from the available data. 
The descriptors applied by studies to their various sub-groups were generally 
recorded in their original form (e.g. novice ecstasy users, polydrug controls), with 
additional information being added if these descriptors were insufficiently detailed. It 
was also noted if the authors had allowed minor infringements of inclusion criteria for 
sub-groups, such as allowing participants with a very low level of cannabis use into 
otherwise drug naïve control groups. The term ‘community sample’ was assigned to 
samples recruited from the general population through advertisements and/or 
outreach activities in the community at large, whilst the term ‘student sample’ was 
assigned to samples recruited entirely through educational institutions. Other 
appropriate descriptive labels were applied to the few studies where the sample’s 
origins were not covered by these three terms. The national origin of each included 
study, with regard to where data was collected, was also recorded. Statistical 
procedures for the control of potentially confounding variables, such age, 
intelligence, and the effects of other drug use by each study were recorded. Details 
of all tasks requiring visual/spatial memory performance were recorded, together 
with the reported findings for these tasks with regard to ecstasy use.  
 
Where studies were included in one or more meta-analysis, the mean and standard 
deviation for each dependent variable (DV) considered appropriate for that analysis 
(see analytic strategy) were recorded for ecstasy user groups and for appropriate 
control groups. The sample sizes for each of these groups were also recorded. The 
direction of difference in performance between groups for each DV included was 
coded as ‘negative’ if it was consistent with an interpretation of ecstasy use having 
affected performance on that task, regardless of the size of difference. For example, 
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if ecstasy users made more errors on a task than controls, this would generally be 
coded as negative. However, on measures of impulsivity the predicted ecstasy 
related effect would be for users to score more highly than controls. Where 
observed, this direction of difference was coded as negative. 
 
Analytic Strategy 
Given the range of information processing and performance demands of the tasks 
identified, analysis for both narrative and quantitative reviewing began with the 
development of a classification system for tasks on the basis of these demands. The 
agreement of a minimum of three reviewers was required for the initial categorisation 
of a task, with other reviewers asked to challenge any classifications they considered 
inappropriate. It should be noted however, that some tasks generated DVs relevant 
to more than one category, in which case the task was noted for both categories. In 
response to these differences in task characteristics, it was decided to conduct meta-
analyses within task categories, rather than including all the studies in one analysis. 
This was done in order to avoid the ‘apples and oranges’ problem whereby data 
which is inherently different in its origins and/or meaning is combined to produce a 
summary main effect of questionable meaning (Lipsey & Wilson, 2001; Borenstein et 
al., 2009). For one task category it was decided that sufficient common ground in 
task demands did not exist for a meaningful meta-analysis to be performed, so that 
performance on tasks in that category is reviewed in narrative form only. In the 
interests of consistency within the meta-analyses, all comparisons of ecstasy users’ 
performance were to the performance of drug using controls, with comparisons to 
drug naïve controls excluded except where the ecstasy users were also naïve to the 
misuse of other drugs. In this way, all inter-group comparisons included in meta-
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analyses had some degree of matching for the use of other drugs. Additionally, 
although all participants had been abstinent from ecstasy and other illegal drugs at 
the time of testing, performance comparisons were not made with groups designated 
as former ecstasy users. Given the evidence that compromised brain functioning 
may return to levels consistent with that of controls in former users (Buchert et al., 
2004; Selvaraj et al., 2009), the inclusion of comparisons of both current and former 
users to controls in the same analysis would potentially confound its interpretation. 
 
Meta-analyses were performed using the means, standard deviations, and group 
sizes (n) for all DVs from studies reporting results from tasks in the respective 
categories. Within each meta-analysis, each study was represented by mean effect 
sizes for all appropriate sub-group comparisons, which in turn represented all of the 
DVs compared for these sub-groups. In this way, our meta-analyses avoided the 
distorting effects of using multiple effect sizes where outcomes are not independent 
due to the same sub-samples of participants having been used in multiple 
comparisons. Studies were excluded from the quantitative aspect of the review if 
they did not compare the performance of ecstasy users to drug using controls (e.g. 
reporting within-participant changes over time), or reported task results in a 
composite form so as to combine DVs of interest with data from other tasks.  In 
cases where task results had not been reported with sufficient clarity for inclusion, 
attempts were made to contact authors for clarification where possible. The effect 
size statistic chosen was Hedges’ g, as this controls for distortions arsing from small 
samples in the more commonly used Cohen’s d statistic (Borenstein et al., 2009). 
For each meta-analysis Rosental’s Fail-safe N is reported, indicating the minimum 
number of studies which would be required to render the result nonsignificant. As 
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only studies in peer reviewed journals were included in this review, this statistic is 
important in the interpretation of meta-analytic results, given the possibility that 
studies reporting significant performance differences between ecstasy users and 
controls  may be more likely to be published. Where studies had reported results for 
appropriate inter-group performance comparisons on relevant tasks, but had been 
excluded from the meta-analysis for some reason, a summary effect size was 
reported for the study so that its results may be seen in the same metric as the meta-
analytic results for that category. 
 
Given the variety of visual tasks employed, and the heterogeneous nature of the 
participant samples with regard to their drug use, it was decided that the 
assumptions for fixed effects models could not be made, and an a priori decision 
was made to only examine results for random effects models.  The choice of random 
effects models in this way, rather than upon the results for heterogeneity in a fixed 
effects model, is currently recommended practice in meta-analysis (Borenstein et al., 
2009). In addition to these performance comparisons between ecstasy users and 
controls, meta-regression (method of moments) was performed using estimated 
lifetime ecstasy consumption (in tablets) as a predictor of effect sizes, where 
estimates were available in this form. As effect sizes consistent with an ecstasy 
related effect were coded as negative, a relationship between these and increasing 
ecstasy consumption would yield a negative coefficient (B). Borenstein et al. 
recommend at least ten studies (or independent sub-groups within studies) per 
predictor in a meta-regression for adequate statistical power. Meta-analyses were 
conducted using Comprehensive Meta-Analysis (CMA 2.0™) software. 
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Results 
Studies and task categories identified 
A total of 325 studies, excluding duplication, were identified by the database 
searches. After checking against the inclusion and exclusion criteria, 52 studies were 
identified for inclusion in the review overall. Whilst 273 may at first seem a large 
number of papers to exclude, it should be noted that the search terms ‘ecstasy’ and 
‘spatial’ led respectively to the identification of some papers from the realms of the 
creative arts and engineering. Other papers were excluded because they reported 
results from animal studies, or were reviews, meta-analyses, or dissertations. 
 
Details of the 52 studies included in the review are summarised in Table 1. From 
these studies a total of 60 separate visual/spatial tasks were identified, although it 
should be noted that some of these tasks were very similar to each other regarding 
the demands they made of participants. These tasks were grouped into four 
categories as shown in Figure 1, with two examples from each category given. It 
should be noted that some studies used tasks from more than one category, so that 
the sum total of studies across categories in Figure 1 exceeds 52. Furthermore, the 
Aggie figures learning test (see Yip & Lee, 2005) and the Rey-Osterreith complex 
figures task (see Bedi & Redman, 2008) yielding dependent variables in both 
Categories 2 and 3. Table 1 records each task included from each study, including 
the category to which it was assigned, so that the tasks contributing to the effect 
sizes in subsequent forest plots for each analysis may be seen. 
Insert Table 1 and Figure 1 about here 
Task Category 1 
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The 16 tasks assigned to this category required participants to recall or recognise 
the spatial distribution of individual stimulus elements presented, such as which cells 
in a computerised grid matrix had been highlighted or the order in which individual 
blocks in an array were to be tapped. Whilst 25 studies employed tasks within this 
category, data for meta-analytic comparisons between ecstasy users and drug using 
controls was only obtainable from 12 studies for a variety of reasons. Four of the 13 
remaining studies had a significant proportion of participants in common with a study 
which was included in the meta-analysis. In the case of Fisk et al. (2006) the 
visual/spatial findings presented were based upon the same sample as for Wareing 
et al. (2005). The three other studies concerned were de Sola et al. (2008; 
overlapping with de Sola Llopiss et al, 2008), Montgomery and Fisk (2008; 
overlapping with Fisk & Montgomery, 2009), and Wareing et al. (2005; overlapping 
with Wareing et al., 2004). These four studies did report results from comparisons 
between ecstasy users and drug using controls, and further details are given below.  
 A further five studies did not report results from such comparisons, reporting instead 
either within-participant comparisons for users or regression analyses (Gouzoulis-
Mayfrank et al., 2005; Indelkofer et al., 2009; Zakzanis & Campbell, 2006; Zakzanis 
& Young, 2001), or comparisons to  apparently drug naïve controls (Hanson & 
Luciana, 2004). Four other studies did not report task results in sufficient detail for 
inclusion, due to a combination of no significant effects having emerged and the 
main focus of the study lying elsewhere (Hoshi et al., 2007; Semple et al., 1999; 
Ward et al., 2006; Wareing et al., 2000). Institutional practices on data disposal 
emerged as one problem in attempts to obtain clarification. 
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The 12 studies included in the meta-analysis yielded 18 a mean weighted effect size 
which was relatively small but highly significant (Hedges g = -0.394; 95% CI -0.608 
(lower) to-0.180 (upper); z = -3.613, p < .000, two-tailed, Rosenthal’s Fail-safe N = 
75 studies), with ecstasy users performing worse than drug using controls. The 
results of this meta-analysis are illustrated in the forest plot in Figure 2. Using 15 
sub-group estimates of lifetime ecstasy tablet consumption from 10 studies, meta-
regression analysis showed a nonsignificant linear relationship between 
consumption and effects sizes (B = -.0004, ns.).  
Insert Figure 2 about here 
Three studies not included in the meta-analysis examined changes over time in 
ecstasy users’ performance on tasks in this category. Performance on a route tracing 
task showed no significant change 1 year after baseline testing (Zakzanis & Young, 
2001), whilst at 2 years from baseline current (i.e. continuing) users in the same 
sample showed performance deficits compared to their 1 year follow up (Zakzanis & 
Campbell, 2006). Former users who had been abstinent from ecstasy for at least 32 
weeks at the 2 year follow up showed no performance decrements in comparison to 
their 1 year follow up performance. However, these findings are based on group 
sizes of eight former users and seven continuing users. With corresponding numbers 
of 17 interim abstainers and 21 continuing users, Gouzoulis-Mayfrank et al. (2005) 
reported no performance changes on a route tracing task  over 18 months for the 
interim abstainers, whilst continuing users actually showed a significant improvement 
in immediate recall and no change in delayed recall performance. In another study 
not employing inter-group comparisons, Indlekofer et al. (2009) reported that lifetime 
frequency of ecstasy consumption was a highly significant predictor in linear 
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regression of omissions on a task which emphasised vigilance, whereas cannabis 
and alcohol consumption were not predictive.  
 
The four studies excluded from the meta-analysis due to sample overlap did report 
results from comparisons between ecstasy users and controls matched for drug use. 
The respective effect size statistics for these studies were de Sola et al (2008: 
Hedges g = -0.105; 95% CI -0.909 (lower) to 0.699 (upper)); Fisk et al. (2006; 
Hedges g = -0.952; 95% CI -1.348 (lower) to -0.556 (upper)); Montgomery and Fisk 
(2008; Hedges g = -0.355; 95% CI -0.987 (lower) to -0.278 (upper)); and Wareing et 
al. (2005; Hedges g = -0.577; 95% CI -1.064 (lower) to -0.089 (upper)). Fisk et al. 
(2006) explored the potentially confounding effects of cannabis consumption for the 
assessment of ecstasy related effects, by examining whether or not visuospatial 
working memory span performance gave any indication that concomitant use of 
cannabis with ecstasy could be associated with either a potential neuroprotective, or 
neurotoxic effect, which would in turn have led to differences when performance was 
compared to that of ecstasy users with no concomitant cannabis use. However, no 
significant performance difference was found. 
 
Whilst a number of studies reported no difference in performance levels on 
measures of spatial span between ecstasy users and controls, some reported that 
the users went on to perform more poorly than the controls if the task was made 
more difficult in some way. This included the introduction of an additional  concurrent  
tasks which drew upon executive resources (Fisk & Montgomery, 2009; Wareing et 
al., 2004, 2005), or under certain circumstances making the task more difficult by 
requiring the backwards recall of a sequence (de Sola Llopis et al., 2008; Halpern et 
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al., 2004). Given the dependence of all visuospatial memory performance upon 
executive resources (Miyake et al., 2001), there is an implication here based upon a 
small number of studies that the appearance of ecstasy related effects may be 
dependent upon the level of overall executive demand at the time of task 
performance. This is would be an important question for further research. 
 
Task Category 2 
The 20 tasks assigned to this category required participants to recognise visual 
displays which had previously been presented. Data for meta-analysis were obtained 
from 16 of the 22 studies in Table 1 identified as using such tasks. Of the remaining 
6 studies not included in the meta-analysis, means and standard deviations for task 
performance were not available for 4 of them (Bolla et al., 1998; Dafters et al., 2004; 
McCann et al., 2009; Semple et al., 1999), due to a variety of reasons such as the 
presentation of results in the form of composite indices reflecting a range of tasks, 
and the presentation of results in graphical forms rather than the presentation of 
precise values. Roiser et al. (2006) appeared to have a significant sample overlap 
with Roiser et al. (2007), the latter study being included in the meta-analysis, whilst 
Gouzoulis-Mayfrank et al. (2005) reported within-participant comparisons for ecstasy 
users. It should be noted that whilst Yip and Lee (2005) used drug naïve controls, 
this matched the drug using profile of their ecstasy users, so that it was possible to 
include this study in the meta-analysis. Furthermore, it was possible to include 
results from McCann et al. (2007) for the matching to sample task from two testing 
sessions occurring prior to catecholamine depletion induced by alpha-methyl-para-
tyrosine (AMPT). Data obtained following AMPT administration fell outside the scope 
of this review. 
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The 16 studies included in the meta-analysis yielded a weighted mean effect size 
which was relatively small but highly significant (Hedges g = -0.379; 95% CI -0.585 
(lower) to -0.173 (upper); z = -3.607, p < .000, two-tailed, Rosenthal’s Fail-safe N = 
135 studies), with ecstasy users performing worse than controls matched for the use 
of other drugs.  The results of this meta-analysis are illustrated in the forest plot in 
Figure 3. Using 14 sub-group estimates of lifetime ecstasy tablet consumption from 
12 studies, meta-regression analysis showed a nonsignificant linear relationship 
between consumption and effect sizes (B = -0.0001, ns.).  
Insert Figure 3 about here 
Gouzoulis-Mayfrank et al. (2005) followed up some of the ecstasy users from their 
earlier sample (Gouzoulis-Mayfrank et al., 2003), and found that performance on the 
logos task (including in his meta-analysis) did not significantly differ from the 
baseline measures taken approximately 18 months earlier for either those who had 
continue to use, or those who had been abstinent since baseline. Roiser et al. (2006) 
examined users and controls with two forms of the serotonin transporter gene-linked 
polymorphism 5-HTTLPR, which had previously been found to be related to 
depression and abnormal emotional processing in users. Unlike tests of some other 
abilities, they reported that performance on neither the matching to sample task, nor 
a pattern recognition task, showed an interaction between participant group and 
genotype, indicating that there was no evidence of a genetic predisposition to 
ecstasy related effects in performance on these tasks. An effect size is not reported 
here for this study because drug using and drug naïve controls were pooled for 
comparisons to ecstasy users, so that an obtained value of Hedges g would not be 
interpretable in the same way as the summary main effect reported above. The 
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finding of Yip and Lee (2005) that ecstasy users showed significantly worse figure 
recognition than controls in their Hong Kong sample is particularly noteworthy 
because both groups were reported to have had no exposure to other illegal drugs, 
and minimal exposure to alcohol and tobacco. Such opportunities to test participants 
free of the potentially confounding effects of other drug use are rare in this research 
field. 
 
Task Category 3 
The 13 tasks assigned to this category required participants to either produce 
original abstract figures, or to reproduce (i.e. recall) figures previously seen. Data for 
meta-analysis were obtained from 12 of the 22 studies identified in Table 1 as using 
studies in this category. Of the remaining 10 studies, 2 had included control 
participants with minimal ecstasy exposure (Schilt et al., 2008, 2010). As minimal 
exposure to ecstasy has been associated with some effects on cognitive 
performance (Schilt et al., 2007), it was decided that it was safer to omit these two 
studies from the analysis. As with Category 1, de Sola et al. (2008) was omitted 
because of sample overlap with de Sola Llopiss et al. (2008), whilst as with category 
2, Roiser et al. (2006) was omitted due to sample overlap with Roiser et al. (2007). 
The use of composite scores for DVs prevented the inclusion of Bolla et al. (1998) 
and McCann et al. (2007), whilst Indlekofer et al. (2009) reported regression 
analyses rather than inter-group comparisons. McCann et al. (2008) focussed upon 
the relationship between task performance and brain activity, rather than inter-group 
comparisons of performance. Two studies reported longitudinal within-participant 
comparisons for users on the WAIS-III Block Design Task (Zakzanis & Campbell, 
2006; Zakzanis & Young, 2001). However, although Medina et al. (2005) did not 
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analyse inter-group performance differences, they did present data suitable for 
inclusion in the meta-analysis. 
 
The 12 studies included in the meta-analysis yielded a mean weighted effect size 
which, once again, was relatively small but highly significant (Hedges g = -0.247; 
95% CI -0.384 (lower) to -0.109 (upper); z = -3.518, p = .000, two-tailed, Rosenthal’s 
Fail-safe N = 21 studies), with ecstasy users performing worse than controls 
matched for the use of other drugs. The results of this meta-analysis are illustrated in 
Figure 4. Using nine sub-group estimates of lifetime ecstasy tablet consumption from 
eight studies, meta-regression analysis showed a nonsignificant linear relationship 
between consumption and effect sizes (B = 0.0005, ns.).  
 
One study excluded from the meta-analysis due to sample overlap did report inter-
group comparison data for performance on the Rey-Osterreith complex figure task 
(de Sola et al., 2008; Hedges g = -0.657; 95% CI -1.476 (lower) to 0.162 (upper)). 
Two studies examined the relationship of performance on tasks in this category to 
different aspects of serotonergic brain functioning. Consistent with their findings for 
tasks assigned in this review to Category 2, Roiser et al. (2006) reported that there 
was no evidence of a genetic predisposition to ecstasy related effects in 
performance on the tile manipulation task associated with alternative forms of the 
serotonin transporter gene-linked polymorphism 5-HTTLPR. In the second study, 
McCann et al. (2008) reported no relationship between performance on the Rey 
Osterreith complex figure task and differences in SERT distribution across a range of 
brain areas between ecstasy users and controls. However, performance on this task 
was negatively correlated with estimated lifetime ecstasy consumption. Indelkofer et 
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al. (2009) also found lifetime ecstasy consumption to be negatively correlated with 
performance on this task. Contrary to predictions, however, Medina et al. (2005) 
found ecstasy consumption measures to be related to better performance on a 
design fluency task. Users’ performance on the WAIS-III Block Design Task was 
found not to have changed over 1 year from baseline testing (Zakzanis & Young, 
2001), nor between 1 year and 2 year follow ups for current (i.e. continuing) users in 
the same sample (Zakzanis & Campbell, 2006). However, between the two follow-up 
points the performance of former users who had abstained from ecstasy for at least 
32 weeks had significantly improved. The limitation of very small numbers of both 
current and former users in this study was previously noted (see Category 1).  
Insert Figure 4 about here 
Task Category 4 
The 13 tasks assigned to this category required a variety of visual/spatial 
judgements to be made which were not deemed to be consistent with the task 
demands characteristic of the other three categories. The heterogeneous nature of 
judgements required by these tasks led to meta-analysis being considered 
inappropriate for this category, as a meaningful interpretation of the result would be 
problematic. Two of the tasks (Raven’s progressive matrices and the Test of Non-
Verbal Intelligence (TONI-3)) are used fairly widely as tests of non-verbal 
intelligence, and did not yield any differences between ecstasy users and controls 
(e.g. Wareing et al., 2005; Yip & Lee, 2005). Furthermore, a reasoning task based 
upon spatial designs within a matrix, which forms part of both the Wechsler Adult 
Intelligence Scale (WAIS-III: Wechsler, 1997a) and the Wechsler Abbreviated Scale 
of Intelligence (WASI: Wechsler, 1997b) showed no differences between ecstasy 
users and controls (Medina et al., 2005; Zakzanis et al., 2002).  
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Only four of the tasks yielded significant performance differences between ecstasy 
users and controls. Using the manikin task, which requires the mental manipulation 
of an object’s spatial orientation, McCann et al. (1999) reported no performance 
differences, whilst subsequently users were reported to show elevated impulsivity 
without impaired accuracy (McCann et al., 2009). Findings from a third study cannot 
be compared with these because the results reported for this task do not distinguish 
between performance before and after chemically induced catecholamine depletion 
(McCann et al., 2007). Two studies examined the tilt aftereffect associated with a 
Gabor, which is a visual stimulus described as “a sinusoidal variation of luminance 
level within a Gaussian window” (Brown et al., 2007 P.441). In effect, participants 
were presented with strips of light and dark areas at a specific angle of orientation to 
the vertical. A range of different angles were tested in these studies (see also 
Dickinson et al., 2009), and it was concluded that differences in tilt aftereffect 
between ecstasy users and controls indicated potential impairment of 
serotonergically mediated lateral inhibition in the occipital visual areas of users. 
There was also a suggestion that concomitant amphetamine use might have some 
protective effect from such changes in the visual systems of ecstasy users. However, 
concomitant cannabis showed no indication of a potential neuroprotective effect in 
relation to the ecstasy related effects observed. In the heading task (Rizzo et al., 
2005) apparent observer motion over the ground was simulated by moving visual 
displays of white dots against a black background, with participants being required to 
indicate their direction of apparent travel in relation to a vertical bar appearing at the 
end of each trial. Users of both ecstasy and cannabis demonstrated poorer 
perception of their angle of travel at 1° and 2° to the vertical, but not at larger angles, 
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compared to regular users of cannabis with no ecstasy exposure and to controls with 
minimal cannabis exposure. Finally, Reay et al. (2006) reported that ecstasy users 
made more errors than controls with a similar profile of use for other substances, on 
the Brixton Spatial Anticipation Task, which tests executive shifting ability in 
discerning the rule governing the spatial location of highlighted visual stimuli. Such 
rules are subject to change without warning as trial progress.  
 
In summary, the small number of tasks in this category showing significant effects 
related to ecstasy consumption, and differences in the nature of the tasks which do, 
limit the any general conclusions which may be drawn beyond the individual studies. 
However, impairments in a basic visual process such as lateral inhibition in occipital 
areas, and in perceived direction of motion may be seen as causes for concern with 
potential implications for everyday life, and as areas for further research. 
 
Controlling potential confounds 
All but a few studies in this review made use of inter-group performance 
comparisons between ecstasy users and non-ecstasy using controls. Given its 
prevalence of use, particular attention was paid to matching ecstasy using and non-
using groups with regard to cannabis use, in order to facilitate conclusions regarding 
the relationship of ecstasy to any inter-group performance differences.  However, it is 
very difficult to match groups exactly on a variable such as cannabis use, and it is 
not feasible to expect that all potential inter-group confounds, which will include a 
broad range of drug use and demographic variables, can be matched in a precise 
way. Table 1 records the use of statistical procedures in the studies reviewed, in 
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order to control for a wide range of potential confounds, in addition to study design 
as shown by the choice of control groups, and between-group matching.  
 
Discussion 
The meta-analyses reported here have shown ecstasy users to have performed 
worse than non-users with comparable patterns of other drug use, on three 
categories of tasks which have different information processing and response 
demands with regard to visual/spatial information. The extent of lifetime ecstasy 
within the general population of various countries (e.g. Hoare & Moon, 2010) makes 
this an important finding. These results are consistent with the wide dispersal of the 
processing of such information from any visual stimulus (Zimmer, 2009) involving 
prefrontal, parietal, temporal, and occipital areas, and the similarly wide dispersal of 
ecstasy related effects on brain functioning. All of the visual stimuli presented will 
have been subject to thalamic and occipital processing where ecstasy users have 
been shown to have either compromised or altered functioning compared to non-
users (Cowan et al., 2006; de Win et al., 2008a, 2008b). The processing of both 
spatial and non-spatial visual information in the DLPFC (Owen et al., 1998; Rypma, 
2006; Zimmer, 2009) of users will have been potentially vulnerable to compromised 
serotonergic functioning due to reduced SERT binding compared to non-users 
(McCann et al., 1998, 2005, 2008). In summary, the present findings do not permit 
conclusions regarding which aspects of visual/spatial information processing may 
have been compromised in ecstasy users compared to non-users. One way forward 
for research, therefore, may be for future scanning and imaging studies to examine 
different characteristics of localised brain activity (e.g. the BOLD signal, SERT 
binding) in the context of performance on specific visual/spatial tasks by the same 
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participants. Despite the attention given to comparing scanning and imaging results 
from the brains of ecstasy users and non-users in the literature, McCann et al. 
(2008) point out that theirs was the first study to report a relationship between 
reduced SERT binding and impaired cognitive functioning in the same participant 
sample. Furthermore, the number of earlier attempts to relate validated markers of 
MDMA neurotoxicity (i.e. validated in laboratory settings using pharmaceutical 
MDMA) to cognitive performance in ecstasy users had been few in number. The 
pursuit of such a strategy for research would help in the precise identification of 
which aspects of visual/spatial information processing, with related neural structures, 
were compromised in ecstasy users, and which were not.  
 
Inverse linear relationships between estimated lifetime ecstasy consumption and 
performance on the visual/spatial tasks in question were reported by a very small 
number of studies in the review, using correlation or regression analyses (e.g. 
Indelkofer et al., 2009; Montgomery & Fisk, 2008; Morgan et al., 2002). Many studies 
did not investigate this question, and others which did either reported no relationship 
between estimated ecstasy consumption and task performance (Bedi & Redman, 
2008; Reneman et al., 2006), combined these task outcomes with data from other 
tasks so that relationships between consumption and individual tasks was not 
reported (Bolla et al., 1998), or in one case reported that estimated lifetime 
consumption was significantly related to better task performance (Medina et al., 
2005). It is important to note that meta-regression using estimated lifetime ecstasy 
tablet consumption as the predictor failed to show a significant linear relationship to 
effect sizes in any of the three categories where quantitative analyses were deemed 
appropriate. Whilst it was not possible to obtain usable estimates from all of the 
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studies in each task category, only the analysis for Category 3 fell below the 
recommended minimum level of ten studies (or independent sub-groups within 
studies) for adequate power in meta-regression (Borenstein et al., 2009), with nine 
independent sub-groups providing consumption data. 
 
The variability found in reporting practices regarding lifetime ecstasy consumption in 
the literature reviewed represents an area which could be addressed in future 
research. The issue of cumulative effects on cognitive performance related to 
estimated lifetime consumption of ecstasy will remain an important one for 
researchers, so that a greater degree of common practice would facilitate its 
exploration. Variability in tablet intake per session over time (Murphy et al., 2006; 
Topp et al., 1999) indicates that reporting lifetime sessions of use is likely to have a 
larger margin of error than estimates of tablet intake based on careful questioning, 
so that the latter would be the preferable measure for reporting.  It should also be 
noted that a linear relationship between ecstasy intake and effects on cognitive 
performance of any sort should not be assumed automatically, with the possibility 
other forms of cumulative relationship being a potential area for possible further 
investigation. For example, might there be one or more levels of consumption 
beyond which the likelihood of impaired performance, increases, decreases, or 
remains unchanged for tasks in difference performance domains? 
 
Of the 52 studies identified in this review, only 1 had a prospective cohort design 
(Schilt et al., 2007). Cross-sectional group designs heavily dominated the remaining 
studies, although some did include an element of longitudinal follow-up. It is clear 
that prospective cohort studies of the relationship between ecstasy use and 
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performance on visual/spatial tasks (and indeed performance on tasks in other 
cognitive domains) constitute a ‘gold standard’ of evidence with regard to maximising 
researchers’ ability to control potential confounds in their analyses (Rogers et al., 
2009). However, reliance on evidence from such studies alone would be problematic 
in itself, given the much smaller number of such studies it would be possible to run 
compared to those with other designs, the length of time required for data collection, 
the limited range of measures it would be possible to include in any one study, and 
the logistical and resource problems inherent in prospective designs. Cross-sectional 
studies are a response to the obvious ethical and legal barriers to administering 
MDMA or placebos to groups of drug naïve volunteers on a double blind basis, and 
measuring subsequent inter-group differences in brain and cognitive functioning. 
Despite their vulnerability to confounds arising from pre-existing inter-group 
differences intelligence, education, other drug use, and a range of other variables, 
they have provided a valuable evidence-base regarding effects on cognitive 
performance related to ecstasy use. Table 1 shows a high level of awareness of 
potential confounds in the majority of studies reviewed, with a range of statistical 
techniques employed to control for them in the results reported. In evaluating the 
contribution of cross-sectional studies to the evidence-base on ecstasy use, it should 
be noted that prospective studies do not recruit users of ecstasy and no other drug, 
so that statistical procedures are also required here to control for other drug use and 
other potential confounds (de Win et al., 2008a; Schilt et al., 2007). However, given 
their vulnerability to confounds, the pre-dominance of cross-sectional studies in the 
ecstasy literature does highlight the need for the replication of findings by different 
research groups, and for clarity in reporting practices to facilitate reviews and meta-
analyses, so that confidence in reported findings may be maximised. The meta-
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analysis reported here were facilitated by studies which reported data at the level of 
group results (means, SDs) for each dependent variable from a task, and hindered 
when only results from composite variables summarising results from a range of 
tasks were reported. In performing meta-analyses, it is recommended that 
researchers be mindful of differences task demands and the related areas of 
performance reported upon, and avoid the ‘apples and oranges’ mistake which can 
make the interpretation of meta-analytic findings problematic (Borenstein et al., 
2009; Lipsey & Wilson, 2001). 
 
In conclusion, this review found that ecstasy users performed worse than controls 
with comparable histories of other drug use on three categories of visual/spatial 
tasks. Whilst the weighted mean effect sizes for each category of these laboratory 
based tasks were relatively small, this does not necessarily mean that there are no 
implications of these findings for ecstasy users in everyday life. Bridging the gap 
between laboratory based findings and everyday life in this area is very difficult, not 
least because task performance in everyday settings is susceptible to many 
influences, and attempts to monitor ecstasy users performance on tasks requiring 
visual/spatial processing in such settings would not only be subject to these 
additional confounds, but would endanger the participant’s right to confidentiality. In 
this context, the performance demands of the tasks reviewed here may be seen as 
proxies for task demands in everyday life, with the demonstrated impaired 
performance of ecstasy users being a cause for concern and further research. 
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